<DOC>
	<DOC>NCT02214628</DOC>
	<brief_summary>The objective is to evaluate the safety of intravitreal Fovista® (anti-PDGF BB) administered in combination with anti-VEGF therapy</brief_summary>
	<brief_title>Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Platelet-derived growth factor BB</mesh_term>
	<criteria>Subjects of either gender aged ≥ 50 years All flourescein angiographic subtypes with presence of active choroidal neovascularization Any intraocular surgery or thermal laser within three (3) months of trial entry. Any prior thermal laser in the macular region, regardless of indication Subjects with subfoveal scar or subfoveal atrophy Any ocular or periocular infection in the past twelve (12) weeks History of any of the following conditions or procedures in the study eye: Rhegmatogenous retinal detachment, pars plana vitrectomy, filtering surgery (e.g. trabeculectomy), glaucoma drainage device, corneal transplant</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Wet AMD</keyword>
	<keyword>Choroidal neovascularization</keyword>
	<keyword>Fovista®</keyword>
	<keyword>E10030</keyword>
	<keyword>Avastin®</keyword>
	<keyword>Eylea®</keyword>
</DOC>